A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients with Advanced Solid Tumors

UVA Tracking #
HSR220050
Principal Investigator
Robert Dreicer
Contact
Contact Phone
Official Trial Title
A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients with Advanced Solid Tumors
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have advanced solid tumors whose disease has progressed despite standard treatments. If you join this study, you will receive an investigational drug called ZX-4081. The purpose of this research is to learn more about the safety of ZX-4081 at different dose levels and to find the highest tolerable dose that can be safely given to patients with advanced solid tumors, and to recommend a dose to be used in future studies. Another purpose of this study is to learn how ZX-4081 affects cancer-specific cells and other blood immunity cells. In addition, the study will look at how long ZX-4081 can be measured in the blood to better understand how the body processes ZX-4081.

Participation of drug treatment may last up to 2 years with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. All study drugs will be administered via an oral tablet.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05118841

uvacancertrials@hscmail.mcc.virginia.edu

Compensation

$70 per study visit; up to $175 per night for a hotel.